Health
Natuzzi Q2 revenue falls 23.4% to €60 million as operating loss widens
Natuzzi (NYSE:NTZ) reported second-quarter 2026 net sales of €60 million, down 23.4% year over year, reflecting persistent weakness in furniture demand.
United States Health
Health
Abbott Q3 sales rise 14.5% to $13.01 billion amid planned Nutrition spinoff
Abbott Laboratories (NYSE:ABT) reported third-quarter 2026 revenue of $13.01 billion, up 14.5% year over year, slightly exceeding Wall Street's $12.99 billion estimate.
Health
Healthcare Services Group records $479.6 million in Q3 revenue
Healthcare Services Group (NASDAQ:HCSG) reported third-quarter 2026 revenue of $479.6 million, up 3.3% year over year, supported by increased demand for outsourced healthcare services.
Health
EU approves Merck’s KEYTRUDA-Padcev bladder cancer regimen
Merck (NYSE:MRK) announced European Commission approval of KEYTRUDA plus Padcev for adults with resectable muscle-invasive bladder cancer, regardless of eligibility for cisplatin-based chemotherapy.
Health
Integra LifeSciences posts third-quarter revenue of $411.2 million
Integra LifeSciences (NASDAQ:IART) reported third-quarter 2026 revenue of $411.2 million, up 2.3% year over year despite supply disruptions at its Cincinnati manufacturing facility.
Health
Elevance Health revenue grows to $50.4 billion in Q3
Elevance Health (NYSE:ELV) reported third-quarter 2026 operating revenue of $50.4 billion, up 0.7% year over year, supported by its diversified healthcare businesses.
Health
Thermo Fisher sales increase 9% to $12.14 billion in Q3
Thermo Fisher Scientific (NYSE:TMO) reported third-quarter 2026 revenue of $12.14 billion, up 9% year over year, supported by growth across its scientific products and services businesses.
Health
Danaher Q3 revenue ralies 8.5% to $6.55 billion
Danaher (NYSE:DHR) reported third-quarter 2026 revenue of $6.554 billion, up 8.5% year over year, supported by growth across its life sciences and diagnostics operations.
Health
Ascentage Pharma receives China breakthrough designation for lisaftoclax combination
Ascentage Pharma (NASDAQ:AAPG) received Breakthrough Therapy Designation in China for lisaftoclax combined with acalabrutinib as a potential first-line treatment for adults with CLL/SLL.
Health
FDA approves GSK’s Hibsago for chronic hepatitis B
GSK (NYSE:GSK) received U.S. Food and Drug Administration approval for Hibsago (bepirovirsen), an RNA-targeted treatment for certain adults with chronic hepatitis B.
Health
HUTCHMED closes $1.3 billion GSK cancer drug licensing deal
HUTCHMED (NASDAQ:HCM) finalized its licensing agreement with GSK (NYSE:GSK) for investigational cancer therapy HMPL-A830, following completion of customary closing conditions and antitrust regulatory reviews.
Health
FDA approves GSK’s Hibsago for chronic hepatitis B
Ionis Pharmaceuticals (NASDAQ:IONS) said partner GSK (NYSE:GSK) received U.S. FDA approval for Hibsago, an RNA-targeted treatment for certain adults with chronic hepatitis B.